CLDN5 and neoplasm: As TMB level is commonly regarded as a remarkable biomarker associated with treatment effects in many immune checkpoint inhibitor (ICI)–treated tumors, CLDN5 mutation predicts the therapeutic efficacy of ICIs across tumor types [16].